Dr. Ricardo Correa breaks down acromegaly—from subtle early signs and delayed diagnosis to treatment strategies and new meds.

Learn about Acromegaly disease, its symptoms like enlarged hands and facial features, and explore effective Acromegaly ...

Imagine living with unexplained changes and health issues for nearly a decade, only to discover it's a rare disease that was, until recently, very difficult to treat and can affect nearly every aspect ...

The journal Pituitary has highlighted research led by Manel Puig, head of the Endocrine, Thyroid and Obesity Research Group ...

Novel nonpeptide SST2 agonist PALSONIFY advances the treatment paradigm as the first once-daily, oral therapy approved by the FDA to treat acromegaly Approval based on data from two pivotal Phase 3 ...

May 29, 2012 (Florence, Italy) — In patients with acromegaly, long-acting-release (LAR) pasireotide (SOM230, Novartis) was more effective than octreotide LAR (Sandostatin, Novartis) at inducing ...

SAN DIEGO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (CRNX) (Nasdaq: CRNX) today announced the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) ...

BOSTON, March 01, 2024 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare ...

Tony's decade of unexplained symptoms led to a rare diagnosis: acromegaly. Dr. Alan Krasner and Tony discuss this overlooked pituitary disorder.

SAN DIEGO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (CRNX) (Nasdaq: CRNX) today announced that the U.S. Food and Drug Administration (FDA) approved PALSONIFY TM (paltusotine) ...